Summary
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
History
NuCana plc was founded in 2014 in Scotland by Dr. Hugh Griffith and Prof. Danny Altmann. The company’s headquarters are now located in Edinburgh, Scotland with an office in Philadelphia, Pennsylvania.
Mission
Our mission is to develop profoundly novel anti-cancer therapeutics that can significantly improve the outcomes of cancer patients.
Vision
NuCana strives to be the best biopharmaceutical company in our space and to have a significant impact on cancer outcomes by discovering and delivering ProTide-based treatments which are safe and effective for patients.
Key Team
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. (Chief Medical Officer)
Martin Quinn (Company Sec.)
Prof. Christopher B. Wood FRCS, M.D., Ph.D. (Chief Medical Officer)
Ms. Theresa Bruce (Sr. VP of Clinical Operations)
Ms. Elisabeth Oelmann (Sr. VP of Medical & Clinical Devel.)
Recognition and Awards
NuCana Plc has received several awards for its work, including the BioIndustry Flock Award from the Scottish government in 2019, the RIS BioStart prize from Scottish Enterprise in 2018, and the EY Scotland Emerging Entrepreneur of the Year Award in 2019.
References
United Kingdom 